Stratrix
On the Record · Lakefront Biotherapeutics

Lakefront Biotherapeutics layoffs, on the record

Every job cut, severance charge and restructuring Lakefront Biotherapeutics reported in its annual reports, 2023 to 2025, quoted from the filings.

Headcount, as reported

Annual reportEmployeesAs of
20-F for 20231,123December 31, 2023

Job cuts, severance and restructuring

  1. Our summaryTransferred its drug discovery and research activities in Romainville, France, along with the employees dedicated to them, to NovAliX. Effective as from July 1, 2023 · Affected: 121 employees

    Word for word“Effective as from July 1, 2023 we transferred our drug discovery and research activities in Romainville, France, and 121 employees exclusively dedicated to the operation of these activities to NovAliX, who assumes all ongoing research and discovery activities in Romainville.” 20-F for 2023
  2. Our summaryAnnounced the departure of Bart Filius, President, COO and CFO and Executive Committee member, with a severance package.

    Word for word“On May 2, 2023, Galapagos announced the departure of Mr. Bart Filius, President, COO and CFO and Executive Committee member per 30 June 2023.” 20-F for 2023
  3. Our summaryPaid a severance amount to Dr. Wigerinck under his severance package. In 2021 · Affected: Dr. Wigerinck · Cost: € 802 thousand

    Word for word“In 2021, an amount of € 802 thousand was paid to Dr. Wigerinck in accordance with Dr. Wigerinck's severance package.” 20-F for 2023
  4. Our summaryFiling reports a discontinuation announcement for the Jyseleca business, dated 2025-01-08, but the excerpt gives no layoff or restructuring details. 2025-01-08

    Word for word“0001421876 ifrs-full:AnnouncementOfPlanToDiscontinueOperationMember 2025-01-08” 20-F for 2024

Lakefront Biotherapeutics has filed no restructuring notice (Form 8-K, Item 2.05) since 2016. Companies file one only for a cut they judge material, so many announced layoffs never appear as one. This page shows what the company reported to the SEC, not news reports or state layoff notices.

Read from Lakefront Biotherapeutics’s annual reports (20-F for 2025, 20-F for 2024, 20-F for 2023) and the financial data it files with the SEC, as of 2026-03-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.